

SEDGWICK LLP
101 Eisenhower Parkway, Suite 300
Roseland, New Jersey 07068
(973) 820-1126
Martin Healy – Attorney I.D. # 78921993
Attorneys for Defendant
Schwarz Pharma, Inc. (n/k/a UCB, Inc.)

FILED
SEP 01 2017
Judge James F. Hyland

IN RE: REGLAN® LITIGATION

THIS DOCUMENT PERTAINS TO:

SCHEDULE A,

Plaintiffs,

v.

WYETH LLC, et al.

Defendants.

SUPERIOR COURT OF NEW JERSEY LAW
DIVISION: MIDDLESEX COUNTY

CASE NO. 289

DOCKET: MID-L-10165-14

**ORDER OF DISMISSAL WITH
PREJUDICE OF PLAINTIFFS'
COMPLAINTS FOR FAILURE TO
PROVIDE UPDATED FACT SHEETS IN
ACCORDANCE WITH CMO 27**

THIS MATTER having been brought before the Court upon motion by Defendants, to dismiss the claims against them in the cases listed in the attached Schedule A, for Plaintiffs' failure to comply with the terms of Case Management Order No. 27, dated June 28, 2017, compelling Plaintiffs to serve a newly completed and recently dated and signed Plaintiff Fact Sheets and accompanying authorizations within thirty (30) days or be subject to dismissal, and the Court having considered the motion and any opposition thereto, and for good cause shown,

IT IS on this 15th day of September, 2017, **ORDERED** that Plaintiffs' complaints and all claims against the Defendants identified on Schedule A in the actions listed on Schedule A are hereby dismissed with prejudice in accordance with Case Management Order No. 27. Plaintiffs' claims against any remaining defendant(s) are not affected by this Order.

Honorable Judge James J. Hyland

SCHEDULE A

Plaintiff Name	Firm	Docket No.	Defendants
Lavalais, Khadija	Medical Legal Consultants of Washington	L-10271-14	Wyeth LLC (f/k/a Wyeth Inc.), Wyeth Holdings Corporation and Wyeth Pharmaceuticals Inc.; Schwarz Pharma Inc. n/k/a UCB, Inc.; Alaven Pharmaceutical LLC; Baxter Healthcare Corporation; Beach Products Inc. and Pharmaceutical Associates, Inc.; Morton Grove Pharmaceuticals, Inc. and Wockhardt USA LLC; Qualitest Pharmaceuticals, Inc.; Generics Bidco I, LLC and Vintage Pharmaceuticals, LLC; Major Pharmaceuticals, Inc. d/b/a Harvard Drug Group LLC; Mutual Pharmaceutical Company, Inc. and United Research Laboratories, Inc.; Northstar RX LLC; Silarx Pharmaceuticals, Inc.; ANI Pharmaceuticals.; Actavis Elizabeth LLC, Purepac Pharmaceutical Co., Alparma, Inc. and King Pharmaceuticals, Inc.; Bristol Meyers Squibb and Apothecon, Inc.; or Ranbaxy Pharmaceuticals, Inc.
Litaker, Preston	Oshman & Mirisola, LLP	L-10131-14	Baxter Healthcare Corporation; Beach Products Inc. and Pharmaceutical Associates, Inc.; Morton Grove Pharmaceuticals, Inc. and Wockhardt USA LLC; Qualitest Pharmaceuticals, Inc.; Generics Bidco I, LLC and Vintage Pharmaceuticals, LLC; Major Pharmaceuticals, Inc. d/b/a Harvard Drug Group LLC; Mutual Pharmaceutical Company, Inc. and United Research Laboratories, Inc.; Silarx Pharmaceuticals, Inc.; ANI Pharmaceuticals.; Actavis Elizabeth LLC, Purepac Pharmaceutical Co., Alparma, Inc. and King Pharmaceuticals, Inc.; Bristol Meyers Squibb and Apothecon, Inc.; or Ranbaxy Pharmaceuticals, Inc.
Thomas, Patricia	Medical Legal Consultants of Washington	L-10270-14	Schwarz Pharma Inc. n/k/a UCB, Inc.; Alaven Pharmaceutical LLC; Baxter Healthcare Corporation; Beach Products Inc. and Pharmaceutical Associates, Inc.; Morton Grove Pharmaceuticals, Inc. and Wockhardt USA LLC; Qualitest Pharmaceuticals, Inc.; Generics Bidco I, LLC and Vintage Pharmaceuticals, LLC; Major Pharmaceuticals, Inc. d/b/a Harvard Drug Group LLC; Mutual Pharmaceutical Company, Inc. and United Research Laboratories, Inc.; Northstar RX LLC; Silarx Pharmaceuticals, Inc.; ANI Pharmaceuticals.; Actavis Elizabeth LLC, Purepac Pharmaceutical Co., Alparma, Inc. and King Pharmaceuticals, Inc.; Bristol Meyers Squibb and Apothecon, Inc.; or Ranbaxy Pharmaceuticals, Inc.